Description of Business

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Description of Business

Note 1. Description of Business

HTG Molecular Diagnostics, Inc. (the “Company”) is a provider of instruments, reagents and services for molecular profiling applications. The Company derives revenue from sales of its HTG EdgeSeq automation system and integrated next-generation sequencing-based HTG EdgeSeq assays, from research services including sample processing and custom research use only (“RUO”) assay design and from collaborative development services.

The Company operates in one segment and its customers are located primarily in the United States and Europe. For the three and six months ended June 30, 2018 approximately 74% and 76% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 34% and 27% for the three and six months ended June 30, 2017. The increase in sales originated by customers located outside of the United States is primarily the result of collaborative development services revenue generated from the Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”), a wholly owned subsidiary of QIAGEN N.V. (see Note 16), which accounted for 80% and 77% of sales to customers located outside of the United States for the three and six months ended June 30, 2018, compared to 46% and 33% for the three and six months ended June 30, 2017.